Biotech Stocks Newsletter – April 10, 2018


GT Biopharma, Inc. (GTBP) Announces it has Completed Enrollment in Proof-of-concept Clinical Trial for its Novel Treatment

GT Biopharma, Inc. announced today that the Proof-of-Concept clinical trial with GTP-011, a novel treatment for the symptoms of motion sickness, that was initiated in late February 2018 is fully enrolled. The study is a single-blind, placebo-controlled, cross-over study. The primary objective of the study will be to demonstrate the anti-motion sickness efficacy of transdermal GTP-011.


Neuralstem, Inc. Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial

Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today announced that it completed the first surgery in the second, cervical injury cohort of a Phase 1 clinical trial in patients with chronic spinal cord injury (cSCI). NSI-566 is Neuralstem’s lead stem cell therapy candidate.

SEE FOR YOURSELF CLICK HERE! is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $1,800,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending April. 30, 2018 to publicly disseminate information about (GTBP). We own zero shares. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER


Please enter your name here
Please enter your comment!